One of the greatest unmet needs in the treatment of Parkinson’s disease(PD)is a disease-modifying therapy,which can halt the ongoing degeneration of dopaminergic neurons that is characteristic of this disorder.Current therapies focus on managing symptoms,rather than on addressing their cause.Promising candidates for disease-modifying therapies are the dopaminergic neurotrophic factors(NTFs).NTFs are secreted One of the greatest unmet needs in the treatment of Parkinson’s disease (PD) is a disease-modifying therapy, which can halt the ongoing degeneration of dopaminergic neurons that is characteristic of this disorder. Current therapies focus on managing symptoms, rather than on addressing cause. Promising candidates for disease-modifying therapies are the dopaminergic neurotrophic factors (NTFs) .NTFs are secreted